Search
Biohaven Ltd
BHVNAdd to Watchlist
15.760USD
+0.880+5.91%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
2.37BMarket Cap
LossP/E TTM
More Details of Biohaven Ltd Company
Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. It is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.
Biohaven Ltd Info
Ticker SymbolBHVN
Company nameBiohaven Ltd
IPO dateSep 23, 2022
CEOCoric (Vlad)
Number of employees256
Security typeOrdinary Share
Fiscal year-endSep 23
Address215 Church Street
CityNEW HAVEN
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountryUnited States of America
Postal code06510
Phone12034040410
Websitehttps://www.biohaven.com/
Ticker SymbolBHVN
IPO dateSep 23, 2022
CEOCoric (Vlad)
Company Executives of Biohaven Ltd
Name
Name/Position
Position
Shareholding
Change
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
2.02M
--
Mr. Matthew (Matt) Buten
Mr. Matthew (Matt) Buten
Chief Financial Officer
Chief Financial Officer
195.65K
+0.28%
Dr. Bruce Car, Ph.D.
Dr. Bruce Car, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
67.72K
+45.11%
Ms. Julia Paige Gregory
Ms. Julia Paige Gregory
Independent Director
Independent Director
25.66K
--
Mr. Michael Thomas (Mike) Heffernan
Mr. Michael Thomas (Mike) Heffernan
Lead Independent Director
Lead Independent Director
15.18K
--
Mr. Robert J. Hugin
Mr. Robert J. Hugin
Independent Director
Independent Director
12.96K
--
Dr. Irina Antonijevic, M.D., Ph.D.
Dr. Irina Antonijevic, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Kishen (Kishan) Mehta
Mr. Kishen (Kishan) Mehta
Director
Director
--
--
Mr. John W. Childs
Mr. John W. Childs
Independent Director
Independent Director
--
--
Ms. Kimberly Gentile
Ms. Kimberly Gentile
Senior Vice President of Clinical Operations
Senior Vice President of Clinical Operations
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
2.02M
--
Mr. Matthew (Matt) Buten
Mr. Matthew (Matt) Buten
Chief Financial Officer
Chief Financial Officer
195.65K
+0.28%
Dr. Bruce Car, Ph.D.
Dr. Bruce Car, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
67.72K
+45.11%
Ms. Julia Paige Gregory
Ms. Julia Paige Gregory
Independent Director
Independent Director
25.66K
--
Mr. Michael Thomas (Mike) Heffernan
Mr. Michael Thomas (Mike) Heffernan
Lead Independent Director
Lead Independent Director
15.18K
--
Mr. Robert J. Hugin
Mr. Robert J. Hugin
Independent Director
Independent Director
12.96K
--
FAQs
Who are the top five shareholders of Biohaven Ltd?
The top five shareholders of Biohaven Ltd are: Dr. Gregory Hugh (Greg) Bailey, M.D.
How many institutions hold shares of Biohaven Ltd (BHVN)?
As of 2026Q1, 610 institutions hold shares of Biohaven Ltd, with a combined market value of approximately 138.20M, accounting for 91.79% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 37866485.00.